Sierra Leone

DEVEX   by Richard Jones                                                         March 17, 2015

(scroll down for link to EU statement.)

As the death toll from Ebola now tops 10,000 in West Africa, donors and aid implementers are figuring out how to best transition from the emergency to the recovery phase of the crisis.

Top EU and U.N. officials, leaders of Ebola-affected nations and representatives from the African Union, nongovernmental organizations, the private sector and the scientific community met in Brussels, Belgium, earlier this month to make progress on this goal. They agreed to embark on the design of a road map to help the economies of Guinea, Sierra Leone and Liberia get back on track, starting with the priority task of rebuilding health systems.

But that, of course, will be no easy feat.

“We are at a really crucial stage of the real fight against Ebola, because this is a turning point when the emergency stage or the emergency response or medical response to Ebola containment is now turning into coordinating and structuring the long-term recovery program,” European Commissioner for International Cooperation and Development Neven Mimica said in an exclusive interview with Devex at the Palais d’Egmont in Brussels.

thelancet.com - Michael Edelstein, Philip Angelides, David L Heymann - February 8, 2015
DOI: http://dx.doi.org/10.1016/S0140-6736(15)60203-3

The resurgence of polio in Syria in 2013 has shown how a breakdown in public health can lead to the re-emergence of previously well-controlled diseases. In 2014 and early 2015 Liberia, Guinea, and Sierra Leone have focused all resources on the Ebola response at the expense of other health programmes. Combined with losing a large proportion of the health-care workforce and the population's reluctance to attend health-care facilities for fear of Ebola, this means the three countries are now at increased risk of other diseases that their health programmes usually target.

(READ COMPLETE ARTICLE) 

REUTERS                                                                                                          March 16, 2015

LONDON  - Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions.

A health worker, left, injects a man in his arm with an Ebola vaccine in Conakry, Guinea, March 7, 2015. The World Health Organization is starting large-scale testing of an experimental Ebola vaccine in Guinea  to see how effective it might be in preventing future outbreaks of the deadly virus.  (AP Photo/ Youssouf Bah)

The Maryland-based biotech company said on Monday its modified vaccinia Ankara (MVA) Ebola Zaire vaccine would be used in an initial Phase I clinical study to be conducted by researchers at the University of Oxford.

Although Ebola case numbers have fallen to a low level, drug companies are still pushing ahead with efforts to develop an effective vaccine, which may help fight the next outbreak, even if it does not come in time for the current epidemic.

QUARTZ  by Grace Dobush                                         March 13, 2015

AUSTIN, Texas—Perhaps the most surprising and important product debuting at SXSW Interactive this year is a personal protective equipment (PPE) prototype for health care workers dealing with Ebola, a tangible result of the U.S. government adapting the culture of innovation and design thinking so key in the startup world.

A team from the U.S. Agency for International Development demonstrated the traditional Ebola suit and the new suit in a preview for Quartz....